Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04526574 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,796
- Enrollment target
NCT04526574 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,796 participants.
The verdict
NCT04526574, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,796 participants
- Enrollment target
Study Summary
Study of the safety and immunogenicity of 20vPnC and influenza vaccine administered at the same visit or separately
Interventions
- OTHER Saline
- BIOLOGICAL Influenza vaccine
- BIOLOGICAL Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,796 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2021-06-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04526574
The ClinicalTrials.gov registry entry for NCT04526574 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,796 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Saline is the first listed.
NCT04526574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04526574 about?
NCT04526574 is a clinical study titled "Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age". Study of the safety and immunogenicity of 20vPnC and influenza vaccine administered at the same visit or separately
What is the current status of trial NCT04526574?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,796 participants. The study started on 2020-09-01. Estimated completion is 2021-06-29.
What interventions are being tested in trial NCT04526574?
The interventions under investigation include: Saline (OTHER), Influenza vaccine (BIOLOGICAL), Experimental 20-valent pneumococcal conjugate vaccine (20vPnC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04526574?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.